575,000 Shares in SAB Biotherapeutics, Inc. $SABS Bought by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC acquired a new position in SAB Biotherapeutics, Inc. (NASDAQ:SABS) in the first quarter, HoldingsChannel.com reports. The institutional investor acquired 575,000 shares of the company’s stock, valued at approximately $2,202,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of SABS. Vivo Capital LLC bought a new position in shares of SAB Biotherapeutics in the 3rd quarter worth about $22,954,000. RA Capital Management L.P. purchased a new stake in SAB Biotherapeutics in the third quarter worth about $8,847,000. Woodline Partners LP bought a new position in shares of SAB Biotherapeutics during the third quarter valued at approximately $5,730,000. Spruce Street Capital LP purchased a new position in shares of SAB Biotherapeutics during the fourth quarter valued at approximately $8,222,000. Finally, Perceptive Advisors LLC purchased a new stake in shares of SAB Biotherapeutics in the 4th quarter worth approximately $3,004,000. 7.82% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

SABS has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of SAB Biotherapeutics in a research note on Wednesday, July 8th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of SAB Biotherapeutics in a research note on Monday, June 15th. Chardan Capital lifted their target price on shares of SAB Biotherapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Wednesday, June 17th. Rodman & Renshaw reiterated a “buy” rating and issued a $13.00 target price on shares of SAB Biotherapeutics in a research note on Monday, May 11th. Finally, Barclays assumed coverage on shares of SAB Biotherapeutics in a research report on Wednesday, June 24th. They set an “overweight” rating and a $13.00 price target for the company. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $12.00.

SAB Biotherapeutics Trading Down 2.0%

Shares of NASDAQ:SABS opened at $3.51 on Friday. The stock has a market capitalization of $268.37 million, a price-to-earnings ratio of -1.66 and a beta of 0.52. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.45 and a current ratio of 11.45. The stock’s 50-day simple moving average is $3.69 and its two-hundred day simple moving average is $3.84. SAB Biotherapeutics, Inc. has a 52-week low of $1.85 and a 52-week high of $5.15.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). Analysts expect that SAB Biotherapeutics, Inc. will post -1.19 EPS for the current year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.